New report questions glucose self-monitoring among noninsulin-dependent Type 2 diabetes patients
NEW YORK There’s no proof that self monitoring of blood glucose by Type 2 diabetes patients not dependent on insulin produces any benefits, according to a recent report by a German healthcare analysis organization.
The Institute for Quality and Efficiency in Health Care also said in its report that it remained unclear whether blood tests had an advantage over urine tests. Blood glucose monitoring remains important for Type 1 and Type 2 patients who do inject insulin, the report noted.
The report by IQWiG — the organization bases its acronym on its German name — used six trials, but came to the conclusion that the data from the trials were not enough to draw any conclusions on the long-term benefit of glucose self-monitoring among noninsulin-dependent Type 2 diabetes patients.
Lilly expands CFO’s role
INDIANAPOLIS Eli Lilly & Co. has expanded the role of its CFO, the drug maker announced Friday.
The Indianapolis-based pharmaceutical manufacture said that CFO and SVP Derica Rice had been promoted to CFO and EVP global services. He will assume the new position on Jan. 1 and be responsible for global services and the company’s ongoing global services design project.
“Derica has demonstrated strong leadership and outstanding results during his 19-year career at Lilly,” Lilly president John Lechleiter said in a statement. “Derica, in his new role, will help ensure that these important functions, aligned with our global services design effort, continue to provide needed support to our business units and our key functions in the most efficient and effective way possible.”
Rice began working for Lilly in 1990 as an international treasury associate and has served in various executive positions, including CFO, of the company’s subsidiaries in Canada and Europe.
FDA approves COPD treatment
RIDGEFIELD, Conn. The Food and Drug Administration has approved an inhaler for reducing the risks of exacerbations associated with chronic obstructive pulmonary disorder.
Pfizer and Boehringer Ingelheim Pharmaceuticals announced the FDA’s approval of Spiriva HandiHaler (tiotropium bromide). The inhaler is already approved as a maintenance treatment for COPD, which includes chronic bronchitis and emphysema.
“Exacerbations of COPD are serious events that can negatively impact the lives of patients,” University of California Los Angeles David Geffen School of Medicine professor emeritus Donald Tashkin said. “People with COPD now have a once-daily treatment option that not only helps them manage the debilitating symptoms of COPD, but also can help them reduce the chance of an exacerbation.”